Effect And Clinical Significance Of Neoadjuvant Chemotherapy On Expressions Of ER, PE, HER-2and Ki-67in Breast Cancer

Background: The present study was designed in an attempt to determinethe influence of neoadjuvant chemotherapy on estrogen receptor (ER),progesterone receptor (PR), human epidermal receptor2(HER-2) and Ki-67expression in patients with breast cancer.Method: Pre-and post-neodjuvant chemotherapy, paired-tumor specimensfrom103patients with breast cancer administrated with anthracycline oranthracycline combining taxane regimen were collected. Immunohistochemicalstaining for ER, PR, HER-2and Ki-67was performed by the DAKO envisionmethod.Results: Among all the103cases,5patients (4.9%) had a completeresponse,82(79.6%) partial response (PR),15(14.6%) stable disease (SD), and1(0.9%) progressive disease (PD), yielding a overall response rate (CR+PR) of 84.5%.9patients achieving pathological complete response (pCR)were notincluded into Immunohistochemical test procedure. There is a significantdecrease of the average index of Ki-67post-neoadjuvant chemotherapy,compared with that before chemotherapy (10%vs32.5%). while the expressionstatus of ER，PR and her-2were changed with no significant difference.Conclusion:1、Neoadjuvant chemotherapy apparently reduced Ki-67index,Ki-67index is one of surrogate markers to predict the treatment response ofneoadjuvant chemotherapy.2、Neoadjuvant chemotherapy did not affect ER, PRand Her-2status. According to ER, PR and Her-2expression pattern before orafter neoadjuvant chemotherapy, therapy strategy for breast cancer is allowed tobe tailored on an individual patient basis.